

# Eric D Hamlett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3784502/publications.pdf>

Version: 2024-02-01

22  
papers

727  
citations

759233

12  
h-index

794594

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1500  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends. , 2022, , 97-128.		0
2	Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease. Molecular Therapy, 2022, 30, 1451-1464.	8.2	14
3	Greater Diffusion Restriction in White Matter in Preclinical Alzheimer Disease. Annals of Neurology, 2022, , .	5.3	6
4	Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain. Journal of Clinical Medicine, 2021, 10, 3931.	2.4	10
5	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. Molecular Syndromology, 2021, 12, 202-218.	0.8	6
6	Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes, macrophage infiltration, and increases I <sup>2</sup> -amyloid protein production in the brain. EBioMedicine, 2021, 74, 103701.	6.1	8
7	Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome. Neurobiology of Disease, 2020, 134, 104616.	4.4	9
8	The role of calbindinâ€28k in a mouse model of Down syndromeâ€related Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042295.	0.8	0
9	RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome. Glia, 2020, 68, 1347-1360.	4.9	24
10	Exosome release and cargo in Down syndrome. Developmental Neurobiology, 2019, 79, 639-655.	3.0	15
11	Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimerâ€s disease. Molecular Neurodegeneration, 2019, 14, 22.	10.8	51
12	Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radical Biology and Medicine, 2018, 114, 110-121.	2.9	64
13	Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. Alzheimer's and Dementia, 2017, 13, 541-549.	0.8	94
14	Alpha-lipoic acid supplementation protects enzymes from damage by nitrosative and oxidative stress. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 36-45.	2.4	28
15	Identification and Characterization of Protein Posttranslational Modifications by Differential Fluorescent Labeling. Neuromethods, 2015, , 243-262.	0.3	0
16	Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Current Alzheimer Research, 2015, 13, 35-52.	1.4	41
17	Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome. Journal of Neuroscience, 2015, 35, 1343-1353.	3.6	61
18	Evidence of altered age-related brain cytoarchitecture in mouse models of down syndrome: a diffusional kurtosis imaging study. Magnetic Resonance Imaging, 2015, 33, 437-447.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Digginâ€² on U(biquitin): A Novel Method for the Identification of Physiological E3 Ubiquitin Ligase Substrates. <i>Cell Biochemistry and Biophysics</i> , 2013, 67, 127-138.	1.8	15
20	Wnt1/ $\beta$ 2-catenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. <i>EMBO Journal</i> , 2012, 31, 429-442.	7.8	252
21	Proteomic analysis of mice expressing human <i>ApoE</i> demonstrates no differences in global protein solubility between <i>ApoE</i> 3 and <i>ApoE</i> 4 young mice. <i>Electrophoresis</i> , 2012, 33, 3745-3755.	2.4	3
22	High-Accuracy Peptide Mass Fingerprinting Using Peak Intensity Data with Machine Learning. <i>Journal of Proteome Research</i> , 2008, 7, 62-69.	3.7	12